-
TRIM21, ERK1/2, and Drug Resistance in Pituitary Adenomas
2026-09-12
The reference study identifies TRIM21 as a context-dependent regulator of pituitary adenoma growth and dopamine-agonist resistance through K27-linked ubiquitination and phosphorylation control of ERK1/2. Its combination of CRISPR screening, biochemical validation, animal studies, and NanoBiT drug screening provides a framework for connecting post-translational signaling to therapeutic response.
-
Tubastatin A for Reliable Cell Assays
2026-09-12
Learn how Tubastatin A (SKU A4101) can improve the interpretation of viability, proliferation, and cytotoxicity experiments through selective HDAC6 inhibition, controlled DMSO formulation, and orthogonal pathway readouts. The article connects practical assay design with recent porcine cardiac-injury evidence while clearly distinguishing biochemical potency from cell-based dose response.
-
MK-571 (L-660,711) Assay Guide
2026-09-11
This scenario-based guide explains how MK-571 (L-660,711) and SKU B7023 can improve experimental control in leukotriene, macrophage, viability, and multidrug-resistance assays. It covers mechanism, DMSO handling, orthogonal endpoint validation, and practical vendor-selection criteria.
-
MK-571: A Dual-Readout Strategy for Inflammation
2026-09-11
MK-571, also known as L-660,711, combines potent cysLT1 receptor antagonism with MRP1-associated transporter activity. This guide develops a dual-readout framework for leukotriene-mediated inflammation research and macrophage drug-resistance assays, helping researchers avoid misleading single-mechanism interpretations.
-
(S)-(+)-Ibuprofen: COX Inhibitor Workflows
2026-09-10
Build more interpretable inflammation assays with the pharmacologically active ibuprofen enantiomer, from enzyme-level COX profiling to cell-based prostaglandin measurements. This guide combines practical dosing, solvent controls, translational design, and troubleshooting for reproducible COX inhibitor research.
-
How (R)-MG132 Strengthens Metabolic Mechanism Studies
2026-09-10
(R)-MG132 is a functionally inactive MG-132 enantiomer that helps separate proteasome-dependent effects from nonspecific cellular responses. This guide shows how to use it as a causal-control tool when studying HNRNPU lactylation, PHGDH regulation, and cancer metabolism.
-
3X (DYKDDDDK) Peptide in Assay Workflows
2026-09-09
Learn how the 3X (DYKDDDDK) Peptide, SKU A6001, can improve traceability of recombinant proteins used in viability, proliferation, and cytotoxicity workflows without being mistaken for a direct viability reagent. This scenario-driven guide covers tag compatibility, storage, metal-sensitive detection, structural workflows, and practical vendor selection.
-
EDTA-Free Protease Inhibitor Cocktail K4002
2026-09-09
The Protease Inhibitor Cocktail is an EDTA-Free Protease Inhibitor formulation for broad-spectrum protection of proteins during cell and tissue extraction. Its 100X DMSO format targets serine, cysteine, acidic, aminopeptidase, and metalloprotease activity, while the referenced LRPPRC–dasatinib study provides a relevant OXPHOS research context rather than direct validation of this reagent.
-
Corynoline Targets Src/JNK in Osteosarcoma
2026-09-08
A 2025 study identifies Corynoline as an anti-osteosarcoma compound that combines G2/M arrest with mitochondrial apoptosis through Src/JNK signaling. Its integrative computational, cellular, and xenograft design provides a useful framework for linking pathway activation to measurable cell-death phenotypes, while also highlighting the need for orthogonal validation.
-
Neem Extract, Oxidative Stress, and Cellular Aging
2026-09-08
Dang et al. connect neem leaf extract with oxidative-stress resistance and lifespan extension across yeast and human cells, combining chemical profiling, network pharmacology, transcriptomics, and genetic validation. The strongest mechanistic evidence implicates catalase encoded by CTT1, while the human-cell experiments provide an important but preliminary bridge toward anti-aging research.
-
LEE011 Succinate: pH-Aware CDK4/6 Assays
2026-09-07
LEE011 succinate is a selective CDK inhibitor for cancer research, but its pH-dependent solubility requires careful assay interpretation. This guide connects ribociclib mechanism, biorelevant dissolution evidence, and practical cell proliferation assay design.
-
Capecitabine in Tumor–Stroma Assembloids
2026-09-05
Capecitabine enables activation-aware chemotherapy studies in patient-derived organoids and assembloids, where stromal context can reveal response patterns hidden by monoculture assays. This workflow connects prodrug biology, Fas-dependent apoptosis, and personalized preclinical oncology research.
-
Aurora A in Retinoblastoma: Evidence for Targeted Therapy
2026-09-05
This 2024 study identifies Aurora kinase A (AURKA) overexpression as a recurring feature of human retinoblastoma and links elevated expression with histopathologic factors associated with aggressive disease. By combining patient-tissue analysis with genetic depletion, pharmacologic inhibition, patient-derived models, xenografts, and mechanistic analysis of MYCN, the work strengthens the rationale for Aurora A–directed preclinical research.
-
Dextrose for Hypoxia and Immunometabolism
2026-09-04
Use Dextrose (D-glucose) to build controlled nutrient conditions for hypoxic tumor models, immune-cell co-cultures, and glucose metabolism research. This practical guide covers stock preparation, concentration-matched workflows, diabetes research extensions, and troubleshooting for more interpretable metabolic data.
-
N1-Methyl-Pseudouridine-5'-Triphosphate Guide
2026-09-04
N1-Methyl-Pseudouridine-5'-Triphosphate, also called N1-Methylpseudo-UTP, is a modified nucleoside triphosphate for producing N1-methylpseudouridine-containing RNA by in vitro transcription. Peer-reviewed evidence indicates that this modification supports accurate translation without significantly changing ribosomal decoding under tested conditions.